{
    "2019-01-09": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Stock Sinks",
                        "Market Gains"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "JP Morgan's Dimon hosted a private dinner for pharma executives, and a major topic was Amazon",
                "features": {
                    "keywords": [
                        "JP Morgan",
                        "Dimon",
                        "Amazon",
                        "pharma executives"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Karyopharm Files MAA for Myeloma Candidate Selinexor in EU",
                "features": {
                    "keywords": [
                        "Karyopharm",
                        "MAA",
                        "Myeloma",
                        "Selinexor",
                        "EU"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Why Johnson & Johnson Stock Fell 12% in December",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Stock Fell",
                        "December"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Visa",
                        "Coca-Cola",
                        "AbbVie",
                        "Johnson & Johnson",
                        "Duke Energy"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "finance",
                        "energy"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "$8 Billion",
                        "Array BioPharma"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "See what the IHS Markit Score report has to say about Johnson & Johnson.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "report",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Innovation Puts Medtronic in the Lead",
                "features": {
                    "keywords": [
                        "Innovation",
                        "Medtronic",
                        "Lead"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Why Johnson & Johnson May Not Have to Pay Its $4.7 Billion Court Verdict",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "$4.7 Billion",
                        "Court Verdict"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Japan Approves Amgen/UCB's Osteoporosis Drug - Will U.S. Follow Suit?",
                "features": {
                    "keywords": [
                        "Japan",
                        "Amgen/UCB",
                        "Osteoporosis Drug",
                        "U.S."
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "Here's What Caused Tandem Diabetes Stock to Gain a Jaw-Dropping 1,509% in 2018",
                "features": {
                    "keywords": [
                        "Tandem Diabetes",
                        "Stock Gain",
                        "1,509%",
                        "2018"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}